Personalis Cash on Hand 2018-2026 | PSNL
Personalis cash on hand from 2018 to 2026. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
|
Personalis Annual Cash on Hand (Millions of US $) |
|
|---|---|
| 2025 | $240 |
| 2024 | $185 |
| 2023 | $114 |
| 2022 | $168 |
| 2021 | $287 |
| 2020 | $203 |
| 2019 | $128 |
| 2018 | $20 |
|
Personalis Quarterly Cash on Hand (Millions of US $) |
|
|---|---|
| 2026-06-30 | $213 |
| 2026-03-31 | $233 |
| 2025-12-31 | $240 |
| 2025-09-30 | $151 |
| 2025-06-30 | $173 |
| 2025-03-31 | $186 |
| 2024-12-31 | $185 |
| 2024-09-30 | $144 |
| 2024-06-30 | $87 |
| 2024-03-31 | $95 |
| 2023-12-31 | $114 |
| 2023-09-30 | $121 |
| 2023-06-30 | $137 |
| 2023-03-31 | $149 |
| 2022-12-31 | $168 |
| 2022-09-30 | $193 |
| 2022-06-30 | $233 |
| 2022-03-31 | $267 |
| 2021-12-31 | $287 |
| 2021-09-30 | $305 |
| 2021-06-30 | $329 |
| 2021-03-31 | $353 |
| 2020-12-31 | $203 |
| 2020-09-30 | $206 |
| 2020-06-30 | $105 |
| 2020-03-31 | $120 |
| 2019-12-31 | $128 |
| 2019-09-30 | $127 |
| 2019-06-30 | $163 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.687B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $44.899B | 17.67 |
| BridgeBio Pharma (BBIO) | United States | $13.352B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $9.749B | 24.85 |
| Aspen Pharmacare (APNHY) | South Africa | $4.248B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.409B | 20.18 |
| Bausch Health Cos (BHC) | Canada | $2.129B | 1.33 |
| Taysha Gene Therapies (TSHA) | United States | $1.652B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $1.019B | 9.58 |
| Assembly Biosciences (ASMB) | United States | $0.519B | 24.98 |
| Sol-Gel Technologies (SLGL) | Israel | $0.178B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.043B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |